ATTOAttovia Therapeutics, Inc.同业对比
Attovia Therapeutics, Inc. 与SIC 2836 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATTO本股 | $700M#6 | — | — | — | — | — | — | — | — | — | 265.8%#1 | — |
| INBX | $1.1B#1 | — | — | 822.6x#6 | 550.0%#2 | -108.3%#12 | -10386.5%#7 | — | — | — | -10.6%#4 | — |
| ODTX | $903M#2 | — | 2.1x#4 | — | — | — | — | 0.0%#1 | — | — | — | — |
| MGTX | $888M#3 | 10.6x#1 | — | 10.9x#3 | 144.6%#3 | 22.7%#3 | -130.2%#2 | — | — | — | 1.9%#2 | — |
| PRME | $808M#4 | — | 20.3x#10 | 174.4x#5 | 55.3%#5 | -2.7%#7 | -4498.1%#6 | -505.3%#11 | — | — | -9.8%#3 | — |
| SANA | $720M#5 | — | 4.7x#5 | — | — | 8.5%#6 | — | -158.0%#9 | — | — | -51.4%#5 | — |
| GRML | $642M#7 | — | 11.1x#8 | — | — | -71.6%#11 | — | -18.2%#3 | -14.6%#1 | — | — | — |
| SLDB | $635M#8 | — | 1.7x#2 | 78.4x#4 | -40.6%#9 | -39.8%#10 | -2214.1%#5 | -46.6%#7 | — | — | — | — |
| FDMT | — | — | — | — | 230194.6%#1 | 12.9%#5 | -187.2%#4 | -34.4%#6 | -44.7%#2 | — | — | — |
| DNA | $620M#9 | — | 1.5x#1 | 3.6x#2 | -25.1%#8 | 42.8%#1 | -185.3%#3 | -0.1%#2 | — | — | — | — |
| CADL | $618M#10 | — | 4.9x#6 | 4940.0x#8 | 0.0%#6 | 30.8%#2 | -38612.8%#8 | -30.3%#4 | — | — | — | — |
| AURA | $617M#11 | — | 2.0x#3 | — | — | -22.2%#9 | — | -33.7%#5 | — | — | — | — |
| ATYR | $602M#12 | — | 12.3x#9 | 3167.2x#7 | -19.1%#7 | -15.8%#8 | -40856.3%#9 | -151.9%#8 | -202.0%#3 | — | — | — |
| RGNX | $470M#13 | — | 6.5x#7 | 2.8x#1 | 104.5%#4 | 14.6%#4 | -94.6%#1 | -270.2%#10 | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-02。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议